| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Forward Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.76 |
| 52 Week High | US$5.45 |
| 52 Week Low | US$1.47 |
| Beta | 1.65 |
| 11 Month Change | 0% |
| 3 Month Change | 1.15% |
| 1 Year Change | -65.15% |
| 33 Year Change | -63.64% |
| 5 Year Change | -85.87% |
| Change since IPO | -98.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1FPB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 4.0% | 0.09% |
| 1Y | -65.1% | -19.3% | 3.1% |
Return vs Industry: 1FPB underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 1FPB underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 1FPB volatility | |
|---|---|
| 1FPB Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 1FPB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 1FPB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 4 | Claus Bo Svendsen | www.forward-pharma.com |
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
Forward Pharma A/S Fundamentals Summary
| 1FPB fundamental statistics | |
|---|---|
| Market cap | €14.06m |
| Earnings (TTM) | -€521.80k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-27.0x
P/E RatioIs 1FPB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1FPB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$566.00k |
| Earnings | -US$566.00k |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 4.7% |
How did 1FPB perform over the long term?
See historical performance and comparison